经过评估，专家小组得出结论，根据现有数据，无法确定大麻提取物作为新型食品的安全性。部分原文报道如下：
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on Cannabis sativa L. extract as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF consists of 57%–65% w/w cannabidiol (CBD) and 9%–17% w/w of other cannabinoids. The NF is produced via supercritical CO2 extraction followed by winterisation, decarboxylation, purification and high-vacuum distillation. It is intended to be used as an ingredient in food supplements at a maximum intake of 30 mg/day. The proposed target population is the adult population, excluding pregnant and lactating women. During the risk assessment, the Panel identified a number of data gaps, which needed to be addressed by the applicant. Therefore, EFSA requested additional information on the identity, production process, compositional data, specifications, genotoxicity, reproductive and developmental toxicity and human data of the NF. The applicant did not reply to these data requests. based on the available data, the Panel concludes that the safety of the NF cannot be established.
本文由食品伙伴网食品资讯中心编辑，供网友参考，有任何疑问，请联系news@foodmate.net。
